We are live on
!
Find out more
OC
Oarsman Capital Portfolio holdings
AUM
$806M
1-Year Est. Return
19.96%
This Fund
S&P 500
This Quarter
Est. Return
+5.53%
1 Year Est. Return
+19.96%
3 Year Est. Return
+61.37%
5 Year Est. Return
+74.92%
10 Year Est. Return
+242.94%
AUM
$237M
AUM Growth
+$17.9M
(+8.2%)
Cap. Flow
+$7.26M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
21.82%
Holding
191
New
8
Increased
79
Reduced
68
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$2.44M |
| 2 |
ProShares Short S&P500
SH
|
+$1.83M |
| 3 |
Range Resources
RRC
|
+$1.33M |
| 4 |
DBD
Diebold Nixdorf Incorporated
DBD
|
+$1.19M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$750K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Motors
GM
|
+$1.31M |
| 2 |
Carnival Corporation Ltd
CCL
|
+$1.11M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$970K |
| 4 |
Citigroup
C
|
+$710K |
| 5 |
DD
Du Pont De Nemours E I
DD
|
+$466K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 10.56% |
| 2 | Consumer Discretionary | 10.49% |
| 3 | Healthcare | 10.29% |
| 4 | Industrials | 10.23% |
| 5 | Technology | 9.98% |
Similar funds
RIM
BCM
GCM
CL
DWA
AF
OWA
BDWCC
Oarsman Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Oarsman Capital held 191 positions worth $237M, up 8.2% from $219M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Oarsman Capital deployed $7.26M of net new capital in Q3 2017, opening 8 new positions and adding to 79 existing holdings. Its largest new stake was ProShares Short S&P500: 13,900 shares worth $1.79M.
By sector, the portfolio is most concentrated in Financials at 11% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $970K trimmed.
- Oarsman Capital's largest Q3 2017 buy was ProShares Short S&P500: 13,900 shares worth $1.79M.
- Oarsman Capital added most to DuPont de Nemours in Q3 2017, an estimated $2.44M increase.
- Oarsman Capital's biggest Q3 2017 reduction was Teva Pharmaceuticals, cutting an estimated $970K.
- Oarsman Capital fully exited General Motors in Q3 2017, selling an estimated $1.31M.
- Oarsman Capital's ten largest holdings make up 22% of its $237M portfolio in Q3 2017.
- Oarsman Capital opened 8 new positions and closed 3 in Q3 2017.
- Oarsman Capital's portfolio value rose 8.2% quarter-over-quarter to $237M.
Based on Oarsman Capital's 13F filing for Q3 2017, filed 13 Nov 2017.